Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4663MR)

This product GTTS-WQ4663MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4663MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3406MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ7843MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ12146MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ7648MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ11477MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ13821MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ3786MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ15834MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW